Related Experiment Video
Updated: Jan 7, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report
Arumugam Manoharan1, Ian Tang2
1Southern Sydney Haematology, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2500, Australia.
Abstract:
We describe a patient with post-essential thrombocythaemia myelofibrosis treated with intermittent hydroxyurea (Hu) therapy (20 mg/Kg, given as a single dose, thrice weekly), achieving sustained disease control and regression of bone marrow fibrosis. Additionally, we discuss the efficacy of and rationale for use of intermittent Hu therapy in patients with myeloproliferative neoplasms, including those deemed to be Hu-resistant or intolerant to the commonly used continuous therapy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Hemodialysis II: Procedure and Complications
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Chronic Kidney Disease II: Clinical Manifestations
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

